I appreciate Steve’s relentless pursuit of the truth and the wealth of information and insights in the comments. I haven’t been able to contribute much because of severe acute health issues experienced by two family members, which I strongly suspect are caused by mRNA drugs.
I thought Maddie de Garay’s diagnosis was MIS-C. I recall an int…
I appreciate Steve’s relentless pursuit of the truth and the wealth of information and insights in the comments. I haven’t been able to contribute much because of severe acute health issues experienced by two family members, which I strongly suspect are caused by mRNA drugs.
I thought Maddie de Garay’s diagnosis was MIS-C. I recall an interview where Stephanie de Garay said she knew there were other cases on the trial. I’m not clear if she meant other cases of MIS-C or other severe AEs but I wondered if they could have been hidden in the 100 cases of reactogenicity Pfizer instructed the FDA to ignore on the trial for ages 12-15:
Note how they exclude cases as myocarditis and in one case, HLH. (Jessica Rose has written about HLH, which is often misdiagnosed as sepsis; note the deaths from sepsis in the Pfizer adult trial) and I recall Steve’s interview with a very impressive nurse Tawny Beuettner who stressed the importance of distinguishing myocarditis from MIS with high troponin levels.
From what Tawny said, I wondered if MIS was what a VERY nervous Queensland CHO John Gerrard was describing at a press conference when he referred to people dropping dead from myocarditis after a short illness. Note how he corrects himself from the “few reports” to “reports”:
As for Covid-associated MIS-C, I write about a biotech that trialed a therapy for Covid-associated ARDS in 2020, recruiting from major hospitals across the USA. The trial failed to meet its primary endpoint of all-cause mortality benefit. I did look into potential corruption by the NIH (which has conflict of interest re. Moderna patents) but came to the conclusion that by mid 2020, there were not enough severe cases. The slow recruitment by mid 2020 was a major clue.
The same therapy was available in an expanded access program for Covid-associated MIS-C. Speaking from memory, I think they treated something like two children during 2020.
The adult trial got very good results in under 65s but failed overall because patients in the latter half were older with depleted T cells.
Given that the therapy is bone marrow-derived mesenchymal stromal cells (MSCs) which respond to peak inflammatory signals, I was wondering if any scientists here could explain how prior treatment with mRNA vaccines might affect (or not) patients’ response to MSCs?
I appreciate Steve’s relentless pursuit of the truth and the wealth of information and insights in the comments. I haven’t been able to contribute much because of severe acute health issues experienced by two family members, which I strongly suspect are caused by mRNA drugs.
I thought Maddie de Garay’s diagnosis was MIS-C. I recall an interview where Stephanie de Garay said she knew there were other cases on the trial. I’m not clear if she meant other cases of MIS-C or other severe AEs but I wondered if they could have been hidden in the 100 cases of reactogenicity Pfizer instructed the FDA to ignore on the trial for ages 12-15:
https://www.fda.gov/media/144245/download#page=42
The study by Yousaf et al. was a master class in whittling down the data to fit the narrative:
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00028-1/fulltext
Note how they exclude cases as myocarditis and in one case, HLH. (Jessica Rose has written about HLH, which is often misdiagnosed as sepsis; note the deaths from sepsis in the Pfizer adult trial) and I recall Steve’s interview with a very impressive nurse Tawny Beuettner who stressed the importance of distinguishing myocarditis from MIS with high troponin levels.
From what Tawny said, I wondered if MIS was what a VERY nervous Queensland CHO John Gerrard was describing at a press conference when he referred to people dropping dead from myocarditis after a short illness. Note how he corrects himself from the “few reports” to “reports”:
https://rumble.com/v1fb34o-37-seconds-doctor-john-gerrard-chief-health-officer-of-qld.html
As for Covid-associated MIS-C, I write about a biotech that trialed a therapy for Covid-associated ARDS in 2020, recruiting from major hospitals across the USA. The trial failed to meet its primary endpoint of all-cause mortality benefit. I did look into potential corruption by the NIH (which has conflict of interest re. Moderna patents) but came to the conclusion that by mid 2020, there were not enough severe cases. The slow recruitment by mid 2020 was a major clue.
The same therapy was available in an expanded access program for Covid-associated MIS-C. Speaking from memory, I think they treated something like two children during 2020.
The adult trial got very good results in under 65s but failed overall because patients in the latter half were older with depleted T cells.
Given that the therapy is bone marrow-derived mesenchymal stromal cells (MSCs) which respond to peak inflammatory signals, I was wondering if any scientists here could explain how prior treatment with mRNA vaccines might affect (or not) patients’ response to MSCs?